Moreover, the 36-month beta value for DNLI is 1.39. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DNLI is 119.11M and currently, short sellers hold a 6.49% of that float. On November 08, 2024, DNLI’s average trading volume was 832.90K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DNLI) stock’s latest price update
Denali Therapeutics Inc (NASDAQ: DNLI) has experienced a rise in its stock price by 0.17 compared to its previous closing price of 29.55. However, the company has seen a gain of 14.02% in its stock price over the last five trading days. globenewswire.com reported 2024-11-06 that SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights.
DNLI’s Market Performance
Denali Therapeutics Inc (DNLI) has experienced a 14.02% rise in stock performance for the past week, with a 11.61% rise in the past month, and a 32.20% rise in the past quarter. The volatility ratio for the week is 5.37%, and the volatility levels for the past 30 days are at 4.16% for DNLI. The simple moving average for the past 20 days is 8.66% for DNLI’s stock, with a 34.27% simple moving average for the past 200 days.
Analysts’ Opinion of DNLI
Citigroup gave a rating of “Buy” to DNLI, setting the target price at $32 in the report published on December 13th of the previous year.
DNLI Trading at 6.98% from the 50-Day Moving Average
After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.88% of loss for the given period.
Volatility was left at 4.16%, however, over the last 30 days, the volatility rate increased by 5.37%, as shares surge +15.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.77% upper at present.
During the last 5 trading sessions, DNLI rose by +14.02%, which changed the moving average for the period of 200-days by +73.00% in comparison to the 20-day moving average, which settled at $27.24. In addition, Denali Therapeutics Inc saw 37.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNLI starting from ALEXANDER SCHUTH, who proposed sale 15,558 shares at the price of $29.55 back on Nov 07 ’24. After this action, ALEXANDER SCHUTH now owns shares of Denali Therapeutics Inc, valued at $459,739 using the latest closing price.
SATO VICKI L, the Director of Denali Therapeutics Inc, sale 3,080 shares at $27.07 during a trade that took place back on Nov 01 ’24, which means that SATO VICKI L is holding 112,076 shares at $83,376 based on the most recent closing price.
Stock Fundamentals for DNLI
Current profitability levels for the company are sitting at:
- 1.65 for the present operating margin
- 1.02 for the gross margin
The net margin for Denali Therapeutics Inc stands at 1.4. The total capital return value is set at -0.37. Equity return is now at value -35.09, with -31.77 for asset returns.
Based on Denali Therapeutics Inc (DNLI), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -6.91. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -23.94.
Currently, EBITDA for the company is -179.97 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of -13.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.98.
Conclusion
To wrap up, the performance of Denali Therapeutics Inc (DNLI) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
